Genascence Corporation Welcomes New Chief Medical Officer
Genascence Corporation, a pioneering clinical-stage biotechnology company dedicated to transforming the treatment landscape for musculoskeletal diseases through innovative gene therapies, has recently appointed Jeymi Tambiah as its Chief Medical Officer. With over 15 years of extensive experience in the biopharmaceutical sector, Dr. Tambiah brings a wealth of knowledge in medical affairs, clinical development, and drug development.
A Leader in the Biopharmaceutical Field
Dr. Tambiah is recognized for his visionary leadership and expertise in creating first-in-class therapeutic programs. His focus spans crucial areas such as osteoarthritis, immunology, oncology, and neuroscience. According to Thomas Chalberg, Ph.D., the founder and CEO of Genascence, "Jeymi is a visionary leader skilled at leveraging scientific and clinical expertise to build innovative first-in-class therapeutic programs, and I am excited to welcome him to Genascence as our chief medical officer." His strategic insights will be vital as the company continues to develop bespoke gene therapies for prevalent musculoskeletal conditions.
Mission and Vision of Genascence
With a strategic emphasis on gene therapy, Genascence has made it its mission to enhance treatment options for individuals suffering from debilitating musculoskeletal diseases. Dr. Tambiah expressed his enthusiasm about joining the extraordinary team at Genascence, stating, "I am thrilled to join this outstanding team under Tom's leadership and apply my knowledge and experience to advance our clinical program so that we can bring potentially curative therapies to patients in desperate need of better treatments." This commitment aligns perfectly with Genascence's dedication to providing life-changing solutions.
Prior Experience and Contributions
Before joining Genascence, Dr. Tambiah served as the Senior Vice President of Clinical Development and External Innovation at Biosplice Therapeutics. In this role, he oversaw clinical programs focusing on innovative molecules aimed at modulating mRNA splicing, particularly for indications in oncology and neurodegenerative diseases. His previous experience at UCB Pharma included launching significant therapeutic products and managing various high-stakes medical affairs projects.
Research and Academic Involvement
Dr. Tambiah's active involvement in the osteoarthritis research community is marked by several prestigious research awards and numerous publications in the field. His engagements extend to committee appointments and presentations at global conferences, highlighting his commitment to education and mentorship in the area of drug development. As the North American representative for the Faculty of Pharmaceutical Medicine UK, he is devoted to the advancement of medical education.
Educational Background
Dr. Tambiah earned his medical degree from the University of Manchester, UK, and holds a doctorate in vascular biology from Imperial College London. He also completed a BSc (Hons) in medical science from the University of St. Andrews. His extensive training has equipped him with a multifaceted approach to medicine and pharmacology.
About Genascence Corporation
Founded in 2017, Genascence Corporation has emerged as a leader in the biopharmaceutical industry by revolutionizing the treatment modalities for musculoskeletal disorders through gene therapy. The company has fostered innovative partnerships with renowned U.S.-based research institutions, including the Mayo Clinic and NYU Langone Health. With its headquarters in Palo Alto, California, Genascence is positioned at the forefront of biotechnology, spearheading advancements that hold the potential to change lives.
Frequently Asked Questions
Who is the new Chief Medical Officer of Genascence?
Jeymi Tambiah has recently been appointed as the Chief Medical Officer of Genascence Corporation.
What experience does Jeymi Tambiah bring to Genascence?
Dr. Tambiah has over 15 years of experience in the biopharmaceutical industry, with expertise in medical affairs, clinical development, and drug development.
What is Genascence's primary focus?
Genascence focuses on developing innovative gene therapies to treat prevalent musculoskeletal diseases affecting many individuals.
Where is Genascence Corporation headquartered?
Genascence Corporation is headquartered in Palo Alto, California.
What educational background does Jeymi Tambiah have?
Dr. Tambiah holds a medical degree from the University of Manchester, a doctorate in vascular biology from Imperial College London, and a BSc (Hons) from the University of St. Andrews.
